NCT07062523View on ClinicalTrials.gov

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2025

Conditions
Sjogren's Syndrome
Interventions
DRUG

68Ga-FAPI

Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga- FAPI will be used to image lesions of Sjögren's syndrome by PET/ CT.

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER